PReoperative Very Low Energy Diets for Obese PAtients Undergoing Non-bariatric Surgery

Obesity Clinical Trial

— PREPARE  

Official title:

PReoperative Very Low Energy Diets for Obese PAtients Undergoing Non-bariatric Surgery: A Randomized Evaluation (PREPARE Pilot)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05918471
• Other study ID #: 15946
• Status: Recruiting
• Phase: N/A
• Start date: January 2, 2024
• Est. completion date: October 31, 2024

Study information

• Verified date: January 2024
• Source: McMaster University
• Contact: Cagla Eskicioglu, MD, MSc
• Phone: 905-522-1155
• Email: eskicio[@]mcmaster.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The PREPARE Pilot randomized controlled trial (RCT) is a multi-center, parallel, blinded RCT that aims to assess the feasibility of a full RCT comparing preoperative very low energy diets (VLEDs) to standard of care prior to elective non-bariatric surgery for obese patients in terms of overall 30-day postoperative morbidity. Adult patients with body mass indices (BMIs) greater than 30 kg/m2 will be randomized 1:1 to receive 3-weeks of preoperative VLED plus preoperative weight loss counselling or preoperative weight loss counselling alone. This trial will enroll patients to assess recruitment, compliance, and follow-up completion to assess the feasibility of a full RCT powered to assess for differences in 30-day postoperative between VLEDs and standard of care arms.

Description:

Obesity is a worldwide epidemic affecting upwards of 700 million people. The economic burden in the United States and Canada are estimated at over $2 trillion and $100 billion United States dollars (USD), respectively, and the resultant healthcare consequences can be devastating for systems and patients alike. Obesity is a systemic disease with devastating consequences for patients undergoing any form of operative intervention. Obese patients presenting in need of medical and surgical intervention are at 2-to-6 fold higher risk of prolonged hospitalization, infectious morbidity, venous thromboembolism, and more. To pre-emptively mitigate some of these concerns, prescribed preoperative weight loss via VLEDs has become a standard of care for obese patients undergoing bariatric surgery (i.e., weight loss surgery). While VLEDs have become a standard in obese patients undergoing bariatric surgery, largely due to the significant reduction of peri-organ fat for better visualization, their application to obese patients undergoing other types of surgery remains limited. A previous systematic review and meta-analysis that identified 13 studies evaluating the use of preoperative VLEDs in obese patients undergoing orthopaedic, vascular, colorectal, upper gastrointestinal, gynecological, and a variety of general surgery procedures for benign disease (e.g., cholecystectomy, abdominal wall hernia). While data were heterogenous, preoperative VLEDs reliably resulted in significant weight loss (3.2-19.2kg) with high rates of compliance to the protocols (94-100%). Adverse event rates were low (<14% in most studies). There were no significant differences in postoperative outcomes, though again pooled analyses included a small number of patients and there were wide corresponding 95% CIs. Overall, this review suggested the evidence for routine use of VLEDs in obese patients undergoing major surgery is compromised by heterogeneous small studies with methodological limitations. A large, definitive trial is required to resolve this uncertainty. Prior to a definitive trial to compare the efficacy of VLEDs in obese patients undergoing major surgery, a pilot RCT is required. A pilot trial will provide the following critical feasibility insights: (1) Assessment of recruitment and randomization ability; (2) Evaluation of compliance to VLED regimens; and (3) Assessment of our ability follow patients completely. The objective of this pilot RCT is to determine the feasibility of a multicenter RCT comparing obese patients (i.e., BMI > 30kg/m2) receiving VLEDs versus control prior to elective non-bariatric surgery in terms of perioperative outcomes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 88
• Est. completion date: October 31, 2024
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Older than 18 years of age
• BMI of greater than 30 kg/m2
• Undergoing major elective non-bariatric surgery. Major surgery is defined as any operation performed under general anesthesia requiring a skin incision extending beyond the subcutaneous tissue.

Exclusion Criteria:

• Undergoing bariatric surgery
• Undergoing neurologic surgery
• Undergoing urgent or emergent surgery
• Recently diagnosed myocardial infarction or unstable angina (i.e., within past six months)
• Diagnosed moderate-to-severe renal dysfunction (i.e., eGFR less than 30mL/min/1.73m2)
• Diagnosed severe liver dysfunction (i.e., cirrhosis, portal hypertension, hepatic encephalopathy, hepatorenal syndrome)
• Recently diagnosed alcohol or drug use disorders (i.e., excessive use of substance within past six months)
• Experienced a recent episode of gout (i.e., within past six months)
• Medical history of porphyria; (10) Known allergy to any Optifast ingredient
• Enrolled in other prospective studies with similar interventions and/or outcomes. Co-enrollment may be deemed appropriate if the steering committees of the respective trials review the details of participation.
• Pregnant or breastfeeding women
• Patients unable to provide informed consent.

Related Conditions & MeSH terms

• Obesity
• Weight Loss

Intervention

Dietary Supplement:
• Very Low Energy Diet with Liquid Supplementation
The preoperative VLED protocol will utilize Optifast 900, a commercially available weight loss product sold by Nestlé Health Sciences. Optifast 900 is designed as a high-protein, low-carbohydrate, and low-fat meal replacement with complete micronutrient composition. Instructions for use are as follows: Consume 4 Optifast 900 packets each day Take 1 sachet of Optifast 900 once in the morning (AM), once at noon, once in the early evening (PM #1), and once later in the evening (PM #2) for three-weeks. Mix 1 sachet with at least 300 mL (1 1/4 cups) of cold water. Shake well or blend in a blender.

Locations

Country	Name	City	State
Canada	Hamilton General	Hamilton	Ontario
Canada	Juravinski Hospital	Hamilton	Ontario
Canada	St. Joseph's Healthcare Hamilton	Hamilton	Ontario
Canada	Kingston Health Sciences Centre	Kingston	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
McMaster University	Queen's University

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recruitment rate	Defined as the number of patients randomized into the RCT per month.	1 year
Primary	Intervention compliance	Defined as the number of preoperative VLED doses taken divided by the total number of doses prescribed for each participant randomized to the intervention arm.	1 year
Primary	Follow-up completion	Defined as completion of the pre-VLED, preoperative, and 30-day postoperative visits, along with complete anthropometric measures and study questionnaires.	1 year
Primary	Network development	Defined as recruiting from all three participating centers at the aforementioned rate. Additionally, we will aim to extend our multi-disciplinary network to at least 10 centers throughout the course of this pilot RCT in preparation for the full RCT.	1 year
Secondary	VLED associated adverse events	The primary safety outcome will be all adverse events deemed secondary to the preoperative VLED. The adverse events will be recorded as dichotomous outcomes and described as either minor or serious, similarly to the OPTIWIN Study; the largest medical weight loss RCT evaluating VLEDs.	Three-week VLED intervention period.
Secondary	Overall 30-day postoperative morbidity	This will be defined as any deviation from the usual postoperative course within 30-days of the index operation and will be a composite of system-specific complications.	30-days following index operation.
Secondary	30-day system-specific complications	Pre-defined system-specific outcomes based on most common postoperative complications following the included types of surgery.	30-days following index operation.
Secondary	30-day postoperative mortality	Death within 30 days of index surgery.	30-days following index operation.
Secondary	Preoperative weight loss	Preoperative weight loss will be assessed by measuring the post-VLED weight on the date of surgery and adjusting for the baseline weight in kg.	Three-week VLED intervention period.
Secondary	Operative time	Operative time will be measured as the time between first skin incision and closure of the last surgical wound in minutes and will be retrieved from the patient EMRs.	Intraoperative
Secondary	Intraoperative blood loss	This will be measured in milliliters and will be ascertained from the patient chart.	Intraoperative
Secondary	Surgeon-perceived technical difficulty	Surgeon-perceived difficulty will be evaluated with a short electronic questionnaire administered immediately following completion of the case.	Intraoperative
Secondary	Postoperative length of stay	This will be measured in days and will be ascertained from the patient chart.	Through postoperative stay, a mean of 3 days
Secondary	Health-related quality of life	Utilizing Short Form-36. The lowest and highest possible scores are 0 and 100, respectively. A higher score is associated with a greater health-related quality of life.	30 days